Stay updated with breaking news from Randomized Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Subgroup analysis of patients with no prior chemotherapy in EMERALD: A phase 3 trial evaluating elacestrant, an investigational oral selective
Investegate announcements from NuCana plc, NuCana Reports First Quarter 2022 Financial Results and Provides Business Update
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Emerald study met both its primary end points of Progression-free survival (PFS) in overall population and in ESR1 mutated patientsPFS rate at 12 months with elacestrant was 22.32% vs. 9.42%
Researchers reported findings that assessed the safety and efficacy of Ensitrelvir among patients with asymptomatic or mild-to-moderate SARS-CoV-2 infection in Japan.